Proceeds will support testing of drugs designed to suppress hunger in people with the tough-to-treat rare disease and, ...
GlobalData on MSN7d
Aardvark prices $94.2m IPO to fund development of Prader-Willi syndrome drugAardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.
Aadvark, which will list on the Nasdaq under the ticker “AARD” Feb. 13, will have the opportunity to bring in roughly $14.1 ...
Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...
Aardvark Wine Lounge, 304 Pine St., in Green Bay opened Jan. 6, 2017 and will officially close on Feb. 21, according to a ...
Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...
雷递网 雷建平 2月8日生物技术公司Aardvark Therapeutics(股票代码为：“AARD”）日前更新招股书，准备2025年2月13日在美国纳斯达克上市。Aardvark ...
Aardvark Therapeutics发行价为16美元，发行588.8万股，募资总额为9421万美元，用于开发其用于治疗罕见疾病普拉德-威利综合征的饥饿抑制药物 ARD-101。 Aardvark ...
根据最新披露，Decheng Capital Global Life Sciences Fund IV, L.P.和Decheng Capital Global Healthcare Fund (Master), LP共同购入了价值2000万美元的Aardvark Therapeutics, Inc. (NASDAQ: AARD ...
Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets are acting as joint book running managers for the offering.
生物技术公司Aardvark Therapeutics近日成功登陆美国纳斯达克市场，股票代码为“AARD”。该公司专注于开发针对罕见疾病普拉德-威利综合征的饥饿抑制药物ARD-101。 据悉，Aardvark ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback